Side-by-side research comparison of Dulaglutide and Tirzepatide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 1 head-to-head study plus 19 on Dulaglutide and 424 on Tirzepatide.
| Dulaglutide | Tirzepatide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist, gip agonist |
| Studies in corpus | 19 | 424 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | cohort · 1 review · 1 rct · 8 other · 4 | other · 3 cohort · 1 rct · 3 review · 2 case report · 1 |
| Studies with explicit sample size | 4 | 4 |
| Head-to-head studies in corpus | 1 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Dulaglutide and Tirzepatide batches we've tested. Aggregate, public data — cross-reference against the studies below.
Fewer than 3 published Dulaglutide COA records so far — not enough for a meaningful purity aggregate yet.
We tested 12737 Tirzepatide batches across 1777 manufacturers, 99.68% avg purity.
Studies in our corpus that mention both Dulaglutide and Tirzepatide — the gold-standard direct comparison evidence.
This methodological study is crucial for advancing the confidence and utility of real-world data in clinical research. Understanding the reliability of claims data emulation for cardiovascular outcomes could significantly accelerate drug development and pos…
Looking for vendor-level purity, endotoxin, and HPLC data on Dulaglutide or Tirzepatide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.